Blurbs

Analysts Offer Insights on Healthcare Companies: HTG Molecular Diagnostics (HTGM) and Galera Therapeutics (GRTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HTG Molecular Diagnostics (HTGMResearch Report) and Galera Therapeutics (GRTXResearch Report) with bullish sentiments.

HTG Molecular Diagnostics (HTGM)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on HTG Molecular Diagnostics, with a price target of $3.00. The company’s shares closed last Wednesday at $0.99, close to its 52-week low of $0.46.

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -12.1% and a 32.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.

Currently, the analyst consensus on HTG Molecular Diagnostics is a Moderate Buy with an average price target of $3.00.

See the top stocks recommended by analysts >>

Galera Therapeutics (GRTX)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Galera Therapeutics today and set a price target of $10.00. The company’s shares closed last Wednesday at $1.32, close to its 52-week low of $1.15.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -41.9% and a 12.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Timber Pharmaceuticals, and Oramed Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Galera Therapeutics with a $6.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on HTGM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed